Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Hedge funds betting on drugs stocks have made bumper profits this year, as a recent wave of deals by big ...
If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...
In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences. From high-stakes ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came ...
Commentary: Biotechnology lets scientists engineer natural ingredients into products, often more sustainably than if they were farmed. Here's what to know. Deenie is a CNET Perspectives contributor ...
Few neighborhoods in Cambridge have seen their fortunes change as dramatically as Kendall Square. Kendall was once known for churning out soap and vulcanized rubber, then manufacturing electronics as ...
In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...
Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...
After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. The question is whether this rally marks a real recovery or just another ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
‘Disheartening? Yes. Surprising? No.’ Report on the future of biotech in Mass. gives a grim outlook.
The industry group MassBio released its annual temperature check on the state’s biotech industry Tuesday, and the results are grim. Both public and private funding have plummeted as federal policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback